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Dyslipidemia and ventricular tachyarrhythmia
Background: Ventricular tachyarrhythmia developing in the acute stage of myocardial infarction (MI) is an
important cause of sudden cardiac death. The aim of this study was to determine whether dyslipidemia is
associated with the occurrence of ventricular tachycardia/fibrillation (VT/VF) during the acute stage of ST-
segment elevation MI (STEMI).
Methods: A total of 58 patients experiencing VT/VF within 24 hours after the onset of MI were selected as the
study group. A group of 58 patients with MI but without VT/VF was selected as the control group matched for
sex (overall, 104 males), age (overall, 58 ( 10 years), and the use of thrombolytic therapy (n = 82). The lipid
profiles including total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein
cholesterol (LDL-C), and triglyceride were measured during the first week and at the third month after the
index MI. Other coronary risk factors, and clinical, hemodynamic and angiographic characteristics were also
included in the assessment.
Results: During the acute stage, patients with VT/VF had higher levels of LDL-C and lower blood pressure on
initial arrival at our hospital. At the 3-month follow-up, those patients with VT/VF showed higher levels of
TC, LDL-C and triglyceride. Multivariate analysis revealed that LDL-C (p < 0.001) at the 3-month follow-up,
mean blood pressure on arrival (p < 0.01), and the difference in triglyceride levels between the first week and
the third month (p < 0.05) were independent predictors for the occurrence of VT/VF in the acute stage of MI.
Conclusion: This study suggests that dyslipidemia imposes a higher risk of developing tachyarrhythmia in
the acute phase of STEMI. [J Formos Med Assoc 2006;105(1):17–24]
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Sudden cardiac death is estimated to account for
approximately 50% of all cardiovascular deaths.
The majority of sudden deaths are attributed to
ventricular tachyarrhythmia, often triggered by
acute ischemic events.1 Lipid-lowering interven-
tions have been shown to reduce coronary events
and all-cause mortality.2–4 It is possible that some
of the beneficial effects of lipid-lowering therapy
can be attributed to the reduction of ventricular
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arrhythmias and sudden death.2,4 Mitchell et al
sought to evaluate the anti-arrhythmic effects of
lipid-lowering therapy in patients enrolled in the
Antiarrhythmics Versus Implantable Defibrillators
(AVID) trial.5 They found that in patients with
atherosclerotic heart disease and implantable
cardioverter-defibrillators (ICD), lipid-lowering
therapy was associated with a reduction in the
probability of ventricular tachycardia/fibrillation
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ventriculography, and serum lipid profile at
the defined points in time. Another 58 patients
matched for age, sex, and the use of thrombolytic
therapy were enrolled as the control group (non-
VT/VF group) if they met criteria 1–3 and 5. The
exclusion criteria were: (1) death within 3 months
after MI; (2) serial examinations not available;
(3) use of lipid-lowering medications, diuretics, or
beta-blockers before admission; (4) previous di-
agnosis of hypothyroidism, chronic liver disease,
nephrotic syndrome, or chronic renal failure; or
(5) previous MI or New York Heart Association
functional class * II before admission.
All patients were closely monitored in the cor-
onary care unit (CCU) for at least 3 days. Records
of baseline characteristics, past medical history,
clinical features, ECG and hemodynamic data of
each patient were collected. Episodes of non- or
sustained VT/VF were recorded automatically
with an arrhythmia monitoring system (Hewlett-
Packard 78510B and 78572B recorder, Hewlett-
Packard Co, Palo Alto, CA, USA). All rhythm
diagnoses were confirmed by the attending phy-
sicians in the CCU. All patients admitted within
6 hours after the onset of MI received intravenous
recombinant tissue-type plasminogen activator
unless contraindicated. The use of aspirin, beta-
blockers, calcium channel antagonists, intravenous
lidocaine, angiotensin-converting enzyme inhibit-
ors, and nitrate preparations was left to the discre-
tion of the attending physicians. Lipid-lowering
medications were not used in any of the patients
during the first 3 months of MI regardless of ini-
tial serum lipid levels.
Determination of serum lipid profiles and
cardiac enzymes
Serum lipids were drawn to determine lipid pro-
files after a 14-hour fast. All patients had their
lipid profiles checked during the first week and
3 months after the acute MI episode. Total choles-
terol (TC), triglyceride and high-density lipopro-
tein cholesterol (HDL-C) serum levels were mea-
sured with an automatic multichannel chemical
analyzer (Hitachi 7450, Hitachi Corp, Tokyo,
Japan) by enzymatic methods. Low-density
(VT/VF) recurrence, suggesting that part of the
benefit of lipid-lowering therapy may be due to
an antiarrhythmic effect. In subjects with isolated
hypercholesterolemia, simvastatin could normal-
ize QTc dispersion and reduce ventricular electri-
cal instability.6 These results suggest that there
might be an association between dyslipidemia and
ventricular arrhythmia. However, no data are avail-
able regarding the direct relationship between dys-
lipidemia and ventricular arrhythmia, especially in
the clinical setting of acute coronary syndrome. Our
recently completed study using a rabbit model of
hypercholesterolemia showed that hypercholeste-
rolemia could induce proarrhythmic neural and
electrophysiologic remodeling in myocardium.7
The purpose of this study was to test the hypothe-
sis that dyslipidemia increases the risk of develop-
ing ventricular tachyarrhythmia in the clinical
setting of acute ST-segment elevation myocardial
infarction (STEMI).
Methods
Study population
An acute myocardial infarction (MI) registration
program has been ongoing at National Taiwan
University Hospital since 1960. A case-control
study was designed including those patients ad-
mitted before 1994, the date of disclosure of the
4S trial.4 These patients did not receive any lipid-
lowering therapy regardless of their serum lipid
levels in the first 3 months after MI. During the
study period from January 1989 to December 1993,
383 patients (310 males and 73 females) were
admitted to the coronary care unit with the diag-
nosis of MI.
This study included a consecutive 58 of these
patients who met the following criteria: (1) chest
pain * 30 minutes in duration; (2) electrocardio-
graphic (ECG) ST-segment elevation * 0.1 mV in
two or more leads; (3) elevated creatine kinase-
MB (CK-MB) isoenzymes within 24 hours of chest
pain; (4) VT/VF recorded on ECG monitor within
24 hours after the onset of chest pain; (5) the meas-
urement of coronary angiography, radionuclide
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lipoprotein cholesterol (LDL-C) concentration was
computed by the Friedewald formula.8 Blood
samples for measuring CK and CK-MB levels were
taken on admission and every 6 hours during the
first 48 hours of hospitalization.
Definition of coronary risk factors
Patients were classified as non-smokers if they
had never smoked or if they had stopped smoking
at least 1 year prior to the MI episode. All other
patients were classified as smokers. Hypertension
was defined as a systolic blood pressure * 150
mmHg and/or diastolic pressure * 95 mmHg with
more than two readings, or for those who had
been taking antihypertensive medication. Diabe-
tes mellitus was defined according to World Health
Organization criteria.9 A positive family history was
defined as a history of premature coronary artery
disease in at least one of the patient’s parents.
Radionuclide ventriculography and coronary
angiography
Resting radionuclide ventriculography was
performed 1 week after infarction, and the left
ventricular ejection fraction (LVEF) was calculated
from the 45$  left anterior oblique projection. Cor-
onary angiography was performed, on average,
on the tenth day of hospitalization. The infarct-
related artery was identified by correlating with
the ST-segment elevations on the admission ECG
and the regional wall motion abnormality in the
left ventriculogram. The infarct-related artery was
classified as patent if the Thrombolysis in Myo-
cardial Infarction (TIMI) perfusion grade was ei-
ther 2 or 3.10 The location of the culprit lesion was
identified according to the 15-segment model rec-
ommended by the American Heart Association.11
Stenoses occluding more than 70% of the arterial
diameter were regarded as significant. The number
of diseased arteries was determined accordingly.
Statistical analysis
Data were presented as mean ( standard deviation
for continuous variables. Absolute and relative
frequency were determined for discrete variables.
Between-group comparisons were done using
Student’s t test for continuous variables and chi-
square test for categorical variables. The lipid pro-
files measured in the first week and 3 months later
were compared using the paired t test. The occur-
rence of VT/VF between different levels of serum
lipids was analyzed using ANOVA with Bonferro-
ni multiple comparisons. Using multiple logistic
regression with stepwise selection, the following
variables were examined to determine the inde-
pendent determinants of the occurrence of ven-
tricular arrhythmias within 24 hours after the onset
of chest pain: age; gender; history of smoking,
hypertension, and diabetes; medications; Killip
classification; mean blood pressure on admission;
LVEF; 3-month post-MI serum lipid profiles and
the difference between the 1-week and 3-month
post-MI serum lipid profiles. Data were analyzed
with the SAS statistical software package, version
6.12 (SAS Institute Inc, Cary, NC, USA). Statistical
significance was assumed for p < 0.05.
Results
Clinical characteristics of study patients
In this case-control study, 58 patients experienc-
ing VT/VF within 24 hours after the onset of chest
pain were matched to 58 patients without VT/VF.
Both groups were matched for gender (104 males),
age (58 ( 10 years), and the use of thrombolytic
therapy (n = 82). The body mass index, risk factors
for coronary artery disease, frequency of previous
angina/stroke, medication history, hemodynamic
data and clinical features of MI on admission in
the two groups are summarized in Table 1. There
were no significant differences in risk factors, past
history of cardiovascular disease, medication use
(except lidocaine) and the features of MI. However,
patients in the VT/VF group had a significantly
lower blood pressure on arrival than did controls.
Serum lipid profiles
The alternations in lipid profiles are summarized
in Table 2. Comparison of the lipid profiles be-
tween the 1st week after MI and 3 months later
revealed that serum TC and LDL-C were signifi-
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cantly lower in the first week. Meanwhile, serum
triglyceride was significantly lower in the acute
phase of MI in patients with VT/VF but not in con-
trols (patients without VT/VF). Comparison of li-
pid profiles between patients with VT/VF and
controls revealed that patients experiencing VT/VF
had higher levels of TC, LDL-C and triglyceride
at 3 months after MI, and a higher level of LDL-C
at admission. The Figure shows the percentages of
VT/VF occurrences in all 116 patients according to
serum lipid profiles at 3 months after MI. VT/VF
occurred more frequently in patients with higher
levels of TC, LDL-C and triglyceride in the acute
phase of MI.
Radionuclide ventriculography and
angiographic findings
Table 3 shows the radionuclide ventriculography
and angiographic findings of the two groups. The
patency rate of infarct-related artery, number of
diseased coronary vessels and locations of the
culprit lesions were similar between the two
groups. There was also no significant difference in
LVEF.
Table 1.  Clinical characteristics of ventricular tachycardia/fibrillation (VT/VF) patients and controls
VT/VF (n = 58) Controls (n = 58) p
Male, n (%) 52 (90) 52 (90) 1.000
Age, yr 57.5 ( 11.0 58.7 ( 8.7 0.256
BMI, kg/m2 23.6 ( 2.7 24.7 ( 2.9 0.050
Past history, n (%)
Previous angina pectoris 26 (45) 24 (41) 0.708
Stroke 5 (9) 2 (3) 0.242
Risk factors, n (%)
Hypertension 24 (41) 20 (34) 0.444
Diabetes mellitus 08 (14) 08 (14) 1.000
Family history 13 (22) 10 (18) 0.485
Current smoking 46 (79) 38 (66) 0.097
Medications*, n (%)
Aspirin 49 (84) 51 (88) 0.590
Beta-blocker 22 (38) 19 (32) 0.560
ACE inhibitor 06 (10) 10 (17) 0.281
Calcium channel blocker 14 (24) 17 (29) 0.529
Nitrate 52 (90) 52 (90) 1.000
Xylocaine 29 (50) 3 (5) < 0.00100
Hemodynamic data†
Heart rate, bpm 76.4 ( 21.1 78.5 ( 16.3 0.549
Blood pressure, mmHg
Systolic 122.0 ( 26.90 134.6 ( 24.60 0.010
Diastolic 72.6 ( 16.3 82.4 ( 15.7 0.001
Mean 89.0 ( 18.7 99.8 ( 17.4 0.002
Clinical features of MI
Location of infarct, n (%)
Anterior 29 (50) 33 (57) 0.457
Other 29 (50) 25 (43)
Q wave MI, n (%) 52 (90) 53 (91) 0.751
Worst Killip class * III, n (%) 09 (16) 3 (5) 0.067
Thrombolytic therapy, n (%) 41 (71) 41 (71) 1.000
Peak CK, IU/L 2622.6 ( 2022.2 2319.3 ( 1689.6 0.382
*Medication used in the first 24 hours after myocardial infarction; †recorded on admission. BMI = body mass index; ACE = angiotensin-
converting enzyme; MI = myocardial infarction; CK = creatine kinase.
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Multivariate analysis of the occurrence of
ventricular arrhythmias
Multiple logistic regression analysis with step-
wise selection was performed to assess the inde-
pendent predictors of the occurrence of VT/VF in
the acute stage of MI. TC level was not included in
the multivariate analysis because of its significant
correlation with serum LDL-C. Multivariate analy-
sis revealed that 3-month LDL-C, mean blood
pressure on admission, and the difference in
triglyceride levels at 1 week and 3 months were
independent predictors of VT/VF occurrence (Table
4). The relative risk of VT/VF occurrence was 3.89
for each 50 mg/dL increase in LDL cholesterol
(95% CI, 1.74–8.69), 1.54 for each 50 mg/dL dif-
ference in triglyceride between 1 week and 3
months (95% CI, 1.01–2.34), and 0.44 for each
20 mmHg increase in mean blood pressure (95%
CI, 0.26–0.75). The 3-month serum LDL-C was
the most significant independent predictor of the
occurrence of VT/VF during the day of acute MI.
No significant multicollinearity among variables
was found.
Discussion
Acute MI is associated with profound alterations
in the serum lipid profile, and these perturbations
in lipid levels persist for about 2 months.12 We,
therefore, used the post-MI serum lipid profile at
the third month as a surrogate for preinfarction
baseline levels.13 In this study, the 3-month
Table 2. Serum lipid profiles 1 week and 3 months after the acute myocardial infarction (MI)
episode in all cases, ventricular tachycardia/fibrillation (VT/VF) patients, and controls
All cases (n = 116) VT/VF (n = 58) Controls (n = 58) p
Total cholesterol, mg/dL
   1 week post-MI 0193.4 ( 34.9* 197.1 ( 34.6. 189.6 ( 35.1 00.247
   3 months post-MI 211.4 ( 40.1 224.6 ( 42.2. 198.2 ( 33.2 < 0.001
HDL cholesterol, mg/dL
   1 week post-MI 36.8 ( 8.8 .35.9 ( 9.7.. 37.7 ( 7.9 00.276
   3 months post-MI 38.9 ( 9.2 .38.1 ( 10.0 39.7 ( 8.3 0.33
LDL cholesterol, mg/dL
   1 week post-MI 130.1 ( 34.2† 137.6 ( 35.60 122.5 ( 31.3 0.02
   3 months post-MI 143.9 ( 37.50 159.4 ( 38.10 128.3 ( 30.0 < 0.0001
Triglyceride, mg/dL
   1 week post-MI 143.9 ( 64.00 144.4 ( 66.2† 143.4 ( 62.2 0.93
   3 months post-MI 158.2 ( 89.30 .0179.8 ( 102.30 136.6 ( 68.4 00.009
*p < 0.001 and †p < 0.01 for comparison with corresponding 3-month values. HDL = high-density lipoprotein; LDL = low-density
lipoprotein.
Figure. Percentages of ventricular tachycardia/fibrillation (VT/VF) occurrence and
different serum lipid levels 3 months after myocardial infarction. LDL = low-density
lipoprotein; HDL = high-density lipoprotein; NS = not significant.
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(baseline) LDL-C and the acute change in trigly-
ceride levels were independent predictors of VT/
VF in patients with acute MI. This study demon-
strated, for the first time, an association between
dyslipidemia and ventricular tachyarrhythmia in
human patients.
Hyperlipidemia and ventricular
tachyarrhythmia
We have previously shown that hypercholestero-
lemia increased the vulnerability of rabbit hearts
to VF.7 The increased vulnerability occurred to-
gether with significant neural and electrophysio-
logic remodeling, but without evidence of signifi-
cant coronary occlusion or MI. The results from
this animal model imply that hypercholesterolemia
can directly trigger neural and electrophysiologic
remodeling, resulting in increased arrhythmogene-
sis. The neural remodeling induced by hypercho-
lesterolemia was characterized by heterogeneous
nerve sprouting and sympathetic hyperinnervation,
which may contribute to the dispersion of repo-
larization during sympathetic activation.14 In ad-
dition to neural remodeling, hypercholesterole-
mia apparently can directly remodel membrane
currents. Our previous studies revealed that sodi-
um currents were decreased and calcium currents
were increased in the hypercholesterolemic cardi-
ac sarcolemma.7,15 The alterations in the membrane
currents were associated with prolonged action
potential duration, longer QTc intervals, and in-
creased repolarization dispersion.7 Interaction be-
tween neural and electrophysiologic remodeling
(i.e. sympathetic stimulation in electrically remod-
eled ventricles) leads to an increase in vulnerabili-
ty to VF.7,16,17 Thus, chronic dyslipidemia could
induce proarrhythmic neural and electrical remod-
eling before the development of acute MI. Increased
sympathetic tone during MI might result in great-
er neural discharges in electrically remodeled
ventricles, leading to VT and VF.
Acute phase changes in triglyceride and
ventricular tachyarrhythmia
The acute phase response to MI has a dramatic
impact on serum triglyceride level.12 In this study,
there were two interesting findings about trigly-
ceride. First, MI is usually associated with an in-
crease in plasma triglyceride levels.12 The same ob-
servation was also made in patients without VT/
VF in the present study. However, patients with
VT/VF had a significant decrease in plasma trigly-
ceride levels during the acute phase of MI. Second,
the baseline (3-month) LDL-C level was more im-
Table 3. Radionuclide ventriculography and angiographic data
for ventricular tachycardia/fibrillation (VT/VF) patients
and controls
VT/VF Controls
(n = 58) (n = 58)
p
Patency of IRA, n (%) 41 (71) 41 (71) 1.00
Location of culprit lesion, n (%)
   LAD 30 (52) 31 (53) 0.852
   LCX 3 (5) 06 (10) 0.298
   RCA 16 (28) 18 (31) 0.683
   Other 09 (16) 3 (5) 0.067
Number of diseased vessels 1.6 ( 0.9 1.8 ( 0.9 0.480
Nuclear LVEF, % 48.4 ( 14.3 50.8 ( 14.1 0.365
IRA = infarct-related artery; LAD = left anterior descending artery; LCX = left circumflex
artery; RCA = right coronary artery; LVEF = left ventricular ejection fraction.
Table 4. Variables significantly related to the occurrence of ventricular arrhythmia by multiple logistic regression
analysis
Estimate OR 95% CI p
3-month LDL-C (for 50 mg/dL increase) 1.3574 3.89 1.74–8.69 0.0009
Mean BP on admission (for 20 mmHg increase) –0.81390 0.44 0.26–0.75 0.0025
Difference in triglyceride: 3 mo – 1 wk (for 50 mg/dL increase) 0.4289 1.54 1.01–2.34 0.0466
Difference in LDL-C: 3 mo – 1 wk (for 50 mg/dL increase) 0.2774 1.32 0.47–3.71 0.5990
3-month triglyceride (for 50 mg/dL increase) 0.0440 1.05 0.71–1.54 0.8246
OR = odds ratio; CI = confidence interval; LDL-C = low-density lipoprotein cholesterol; BP = blood pressure.
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portant than the acute phase changes in the pre-
diction of VT/VF. However, for triglyceride, the
acute phase change is more important in the pre-
diction of VT/VF.
Differences between triglyceride levels at 1
week and 3 months may be a reflection of ongo-
ing lipolysis, which is frequently accelerated dur-
ing the acute stress after MI. Increased lipolysis
results in an increase in plasma free fatty acids
(FFA). Circulating nonesterified fatty acid level
has been shown to be a predictive risk factor for
sudden death.18 Proarrhythmic mechanisms of in-
creased plasma FFA are numerous and complex.19
An accumulation of tissue FFA during ischemia
could modulate the potassium channels.20 The
long-chain fatty acid, acylcarnitine, would activate
calcium channels to produce a direct arrhythmo-
genic effect through calcium overload.21 Thus, in-
creased lipolysis during acute ischemia would re-
sult in increased circulating FFA, which would, in
turn, contribute to arrhythmogenesis. Moreover,
increased plasma FFA during the acute phase of
MI is mediated largely by sympathetic stimula-
tion,22 which by itself is also proarrhythmic. Our
previous study in hypercholesterolemic rabbits also
showed that hypercholesterolemia resulted in sym-
pathetic hyperinnervation.7 Therefore, the acute
change in triglyceride level may be both a conse-
quence of sympathetic hyperinnervation and a con-
tributory factor to VT/VF during acute MI.
Study limitations
This study had several important limitations. The
case-control design of this study is particularly
prone to bias. The cases and controls must be suf-
ficiently similar to avoid bias.23 In this study,
however, the cases matched well with the controls.
This carries a risk of “overmatching”, which dimin-
ishes the ability of a study to detect a significant
predictor. This may explain why the Killip class
was not a predictor of VT/VF in this study. Even
with good matching, dyslipidemia was still an
independent risk factor of VT/VF in the present
study. Because of the well documented beneficial
effects of lipid-lowering therapy, it is no longer
ethical to withhold lipid-lowering intervention in
the first 3 months after MI. Therefore, it is not pos-
sible to conduct a prospective randomized trial to
test this hypothesis.
The finding that LVEF was not an independent
predictor of VT/VF in this study may have been
related to the following study limitations: meas-
urement of LVEF about 1 week after the occurrence
of MI, as opposed to at the onset of arrhythmia;
and the small sample size and “overmatching”
effect of this case-control study. Reduced LVEF
remains an important risk factor for total mortali-
ty and sudden cardiac death in post-MI survivors.
However, it may not be true in VT/VF triggered by
acute myocardial ischemia (acute stage of MI) in
patients without preexisting myocardial scarring.1
Meanwhile, when LVEF is severely depressed (< 15–
20%), the prevailing mode of cardiac death is
non-sudden, or, when sudden, it is often related
to bradyarrhythmias or electromechanical dissoci-
ation rather than VT/VF.24 LVEF was also not pre-
dictive for recurrence of ventricular arrhythmias
in some ICD studies.25,26
Another study limitation was the exclusion of
patients who died within 3 months or who could
not be followed up for at least 3 months after MI
in order to obtain serum lipid profiles that could
reflect baseline lipid status. This inevitably led to
selection bias and exclusion of patients with poor
prognosis. However, because dyslipidemia is a
poor prognostic indicator, the exclusion of patients
with higher risk should theoretically lead to un-
derestimation of the possible association between
dyslipidemia and VT/VF, rather than overesti-
mation.
Conclusion
In conclusion, dyslipidemia is an independent
predictor of VT/VF in the acute phase of MI. It is
possible that baseline serum lipid and triglyceride
levels during the acute phase of MI played a signi-
ficant role in the arrhythmogenesis. These results
may also partially explain the beneficial effects of
lipid-lowering drugs in reducing the risk of sud-
den cardiac death in large-scale clinical trials.
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